We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TZOO:NASDAQTravelzoo Analysis

Data as of 2026-08-02 - not real-time

$7.23

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Travelzoo is trading well below its longer‑term moving average, with the short‑term average still under the 50‑day trend line, indicating a neutral price bias. The relative strength index sits in oversold territory, while the MACD histogram remains negative, suggesting lingering bearish momentum. Despite a recent modest revenue uptick in the latest quarter and a surge in membership, operating margins are still negative and the company posts a very high trailing P/E relative to its industry peers. The DCF‑derived fair value is substantially lower than the current market price, and the market’s extreme greed sentiment amplifies the valuation disconnect. With volatility approaching double‑digit annualized levels, a beta above one, and a history of steep drawdowns, the stock carries heightened risk, especially given its small market cap and limited liquidity. In this context, the technical picture hints at a short‑term bounce potential, but fundamental weaknesses and overvaluation weigh heavily on medium‑ to long‑term outlook.
Investors should therefore treat the stock as a high‑risk, overvalued play that may offer a fleeting technical rebound but lacks a compelling long‑term value case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • oversold RSI suggesting potential short‑term bounce
  • bearish MACD indicating continued downside pressure
  • price hovering just above the identified support level

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • persistent negative operating margins and high trailing P/E
  • modest revenue growth but limited margin improvement
  • valuation gap between market price and DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • significant overvaluation relative to peers and intrinsic value
  • high volatility and beta amplifying downside risk
  • lack of dividend and uncertain path to sustainable profitability

Key Metrics & Analysis

Financial Health

Revenue Growth-2.90%
Profit Margin0.51%
P/E Ratio120.5
ROA2.28%
P/B Ratio-9.1
Op. Cash Flow$3.3M
Free Cash Flow$3.0M
Industry P/E15.7

Technical Analysis

TrendNeutral
RSI22.2
Support$6.68
Resistance$12.00
MA 20$10.11
MA 50$10.39
MA 200$7.97
MACDBearish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Fair Value$3.75
Target Price$19.63
Upside/Downside171.44%
GradeOvervalued
TypeValue

Risk Assessment

Beta1.17
Volatility96.29%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.